Serum levels of pantropic p53 protein and EGF-receptor, and detection of anti-p53 antibodies in former uranium miners (SDAG Wismut)

American Journal of Industrial Medicine

Volumn 36, Issue 6, 1999, Pages 602-609

  Schneider, Joachim ^a   Presek, Peter ^b   Braun, Alexandra ^b   Woitowitz, Hans Joachim ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b JUSTUS LIEBIG UNIVERSITY GIESSEN   (Germany)

Author keywords

Anti p53 antibodies; EGF R; Ionizing radiation; P53 protein; Radon; Schneeberg lung cancer; Serum

Indexed keywords

ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN P53;

ADULT; AGED; ANTIBODY DETECTION; ARTICLE; CONTROLLED STUDY; HUMAN; IONIZING RADIATION; LUNG CANCER; MAJOR CLINICAL STUDY; MINER; OCCUPATIONAL CARCINOGENESIS; PROTEIN DETERMINATION; RADIATION CARCINOGENESIS; URANIUM MINE;

AGED; ANTIBODIES; GERMANY; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; MINING; OCCUPATIONAL DISEASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; URANIUM;

EID: 0032750249     PISSN: 02713586     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0274(199912)36:6<602::AID-AJIM2>3.0.CO;2-M     Document Type: Article

References (57)

1. Angelopoulou K, Diamandis KE, Sutherland DJ, Kellm JA, Bunting PS. 1994. Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers. Int J Cancer 58:480-487.
2. Barker S, Vinson GP. 1990. Epidermal growth factor in breast cancer. Int J Biochem 22:939-945.
3. Bartsch H, Hollstein M, Mustonen R, Schmidt J, Spiethoff A, Wesch H, Wiethege T, Müller KM. 1995. Screening for putative radon-specific p53 mutation hotspot in German uranium miners. Lancet 346:121.
4. Bauer HD. 1997. Staubbelastungen in untertägigen Betrieben der ehemaligen Wismut während der Frühphase der Uranerzgewinnung nach dem 2. Weltkrieg. (Potential dust exposures in underground mines of the former Wismut Ltd. during early phase of uranium mining after the Second World War.) Gefahrstoffe Reinh Luft 57: 349-354.
5. Birrer MJ, Brown PH. 1992. Application of molecular genetics to the early diagnosis and screening of lung cancer. Cancer Res 52: 2658s-2664s.
6. Brambilla E, Gazzeri S, Moro D, Caron de Fromental C, Gouyer V, Jacrot M, Brambilla C. 1993. Immunohistochemical study of p53 in human lung carcinomas. Am J Pathol 143:199-210.
7. Brandt-Rauf PW, Smith S, Hemminki K, Koskinen H, Vainio H, Niman H, Ford J. 1992. Serum oncoproteins and growth factors in asbestosis and silicosis patients. Int J Cancer 50:881-885.
8. Brandt-Rauf PW. 1995. The c-erbB transmembrane growth factor receptors as serum biomarkers in human cancer studies. Mutation Res 333:203-208.
9. Brüske-Hohlfeld I, Möhner M, Wichmann HE. 1997. Predicted number of lung cancer cases in Germany among former uranium miners of the Wismut. Health Phys 72:3-9.
10. Burkhart C. 1994. Das Tumorsuppressorprotein p53. (The tumor suppressor protein p53) Dtsch Ärzteblatt 91:898-904.
11. Butz M. 1996. Beruflich verursachte Krebserkrankungen. (Occupationally derived cancers) Schriftenreihe des Hauptverbandes der gewerblichen Berufsgenossenschaften, St. Augustin.
12. Fontanini G, Fiore L, Bigini D, Vignati S, Calvo S, Mussi A, Lucci M, Angeletti CA, Merlo Basolo F. 1994. Levels of p53 antigen in serum of non-small cell lung cancer patients correlate with positive p53 immunohistochemistry on tumor sections, tumor necrosis and nodal involvement. Int J Oncol 5:553-558.
13. Greenberg M, Selikoff IJ. 1993. Lung cancer in the Schneeberg mines: a reappraisal of the data reported by Harting and Hesse in 1879. Ann Occup Hyg 37:5-14.
14. Haeder M, Rotsch M, Bepler G, Henning C, Havemann K, Heimann B, Moelling K. 1988. Epidermal growth factor receptor expression in human lung cancer cell lines. Cancer Res 48:1132-1136.
15. Hagmar L, Bonassi S, Stromberg U, Brogger A, Knudsen LE, Norppa H, Reuterwall C. 1998. Chromosomal aberrations in lymphocytes predict human cancer: A report from the European Study Group on Cytogenetic Biomarkers and Health (ESCH). Cancer Res 58:4117-4121.
16. Hanaoka T, Yamano Y, Katsuno N, Kagawa J, Ishizu S. 1997. Elevated serum levels of pantropic p53 in chronium workers. Scand J Work Environ Health 23:37-40.
17. Harris CC, Hollstein M. 1993. Clinical implications of the p53 tumor-suppressor gene. New Engl J Med 329:1318-1327.
18. Hollstein M, Sidranski D, Vogelstein B, Harris CC. 1991. p53 mutations in human cancers. Science 253:49-53.
19. Husgafvel-Pursiainen K, Kannio A, Oksa P, Suitiala T, Koskinen R, Hemminiki K, Smith S, Rosenstock-Leibu R, Brandt-Rauf P. 1997. Mutations, tissue accumulations, and serum levels of p53 in patients with occupational cancers from asbestos and silica exposure. Environ Mol Mutagen 30:224-230.
20. Kaye FJ, Kim YW, Otterson GA. 1995. Molecular biology of lung cancer. In: Cowell JK, editor. Molecular genetics of cancer. Oxford: BIOS Scientific Publishers, p 179-204.
21. Lahdeaho ML, Lehtinen T, Aine R, Hakala T, Lehtinen M. 1994. Antibody response to adenovirus E1b-derived synthetic peptides and serum levels of p53 in patients with gastrointestinal and other malignant lymphomas. J Med Virol 43:393-396.
22. Lahat N, Froom P, Kritsl-Boneh E, Cohen C, Lerman Y, Ribak J. 1999. Increased serum concentrations of growth factor receptors and Neu in workers previously exposed to asbestos. Occup Environ Med 56:114-117.
23. Lehtinen T, Luostarinen T, Dillner J, Aromaa A, Hakama M, Hakulinen T, Knekt P, Leinikki P, Lumio J, Lahdeaho ML, Maatela J, Teppo L, Lehtinen M. 1996. Serum p53 accumulation and altered antibody responses to Epstein-Barr virus proteins precede diagnosis of haemopoietic malignancies of lymphoid origin. Br J Haematol 93:104-110.
24. Levesque MA, D'Casta M, Diamandis EP. 1996. p53 protein is absent from serum of patients with lung cancer. Br J Cancer 74:1434-1440.
25. Lubin R, Zalcman G, Bouchet L, Tredaniel J, Lagros Y, Cazals D, Hirsch A, Soussi T. 1995. Serum p53 antibodies as early markers of lung cancer. Nat Med 1:701-702.
26. Luo JC, Zehab R, Antilla S, Ridanpää M, Husgafvel-Pursiainen K, Vainio H, Carney W, DeVivo J, Milling C, Brandt-Rauf PW. 1994. Detection of serum p53 protein in lung cancer patients. J Occup Med 36:155-160.
27. Micelli G, Donaded A, Quaranta M. 1992. The p53 tumor suppressor gene. A preliminary clinical study in breast cancer patients. Cell Biophys 21:25-31.
28. Minna JD. 1993. The molecular biology of lung cancer pathogenesis. Chest 103:449-456.
29. Mudenda B, Green JA, Green B, Jenkins JR, Robertson L, Tarunina M, Leinster SJ. 1994. The relationship between serum p53 auto-antibodies and characteristics of human breast cancer. Br J Cancer 69:1115-1119.
30. Müller WU, Streffer C. 1994. Micronucleus assays. Adv Mutag Res 5:1-133.
31. Nuorva U, Makitaro R, Huhti E, Kamel D, Vähäkangas K, Bloigu R, Soini Y, Paakko P. 1994. p53 protein accumulation in lung carcinomas of patients exposed to asbestos and tobacco smoke. Am J Respir Crit Care Med 150:528-533.
32. Partanen R, Hemminki K, Koskinen H, Luo JC, Carney WP, Brandt-Rauf PW. 1994a. The detection of increased amounts of the extracellular domain of the epidermal growth factor receptor in serum during carcinogenesis in asbestosis patients. J Occup Med 36: 1324-1328.
33. Partanen R, Hemminki K, Brandt-Rauf PW, Jin CG, Koskinen H. 1994b. Serum levels of growth factor receptors, EGFR and Neu in asbestosis patients: a follow-up study. Int J Oncol 4:1025-1028.
34. Pavelic K, Banjac Z, Pavelic J, Spaventi S. 1993. Evidence for a role of EOF receptor in the progression of human lung carcinoma. Anticancer Res 14:1133-1137.
35. Plappert U, Raddatz K, Roth S, Fliedner TM. 1995. DNA-damage detection in man after radiation exposure - the comet assay - its possible application for human biomonitoring. Stem Cells 13:215-222.
36. Preudhomme C, Lubin R, Lepelley P, Vanzumbeke M, Fenaux P. 1994. Detection of serum anti p53 antibodies and their correlation with p53 mutations in myelodysplastic syndromes and acute myeloid leukemia. Leukemia 8:1589-1591.
37. Rosenfeld MR, Malats N, Schramm L, Graus F, Cardenal F, Vinolas N, Rosell R, Tora M, Real FX, Posner JB, Dalmau J. 1997. Serum anti-p53 antibodies and prognosis of patients with small-cell lung cancer. J Nat Cancer Inst 89:381-385.
38. Rusch V, Baselga J, Cordon-Cardo J, Orazem J, Zaman M, Hoda S, McIntosh J, Kurie J, Dmitrovsky E. 1993. Differential expression of the epidermal growth factor receptor and its ligands in primary non small cell lung cancers and adjacent benign lung. Cancer Res 53:2379-2385.
39. Schlichtholz B, Tredaniel J, Lubin R, Zalcman G, Hirsch A, Soussi T. 1994. Analysis of p53 antibodies in sera of patients with lung carcinoma define immunodominant regions in the p53 protein. Br J Cancer 69:809-816.
40. Schuttmann W. 1993. Schneeberg lung diseases and uranium mining in the Saxon Ore mountains (Erzgebirge). Am J Ind Med 23: 355-368.
41. Segawa Y, Tagigawa N, Mandai K, Maeda Y, Takata I, Fujimoto N, Jinno K. 1997. Measurement of serum p53 protein in patients with small cell lung cancer and results of its clinicopathological evaluation. Lung Cancer 16:229-238.
42. Selig R. 1995. Erfahrungen zu Krebserkrankungen infolge "Wismut-Tätigkeit" und gutachterliche Gesichtspunkte. (Lung cancer following Wismut employment) Manuskript zum Vortrag auf dem IV. Karlshorster Kolloquim, Berlin, 29 May 1995.
43. Smith S, Schecter A, Papke O, Do T, Coulibaly D, Brandt-Rauf P. 1998. Quantitation of the extracellular domain of the epidermal growth factor receptor in the plasma of dioxin-exposed individuals. Am J Ind Med 34:1-5.
44. Sorscher SM, Russak V, Graziano V, Cagle M, Feramisco JR, Green MR. 1995. Immunohistochemical evaluation of E-cadherin and epidermal growth factor receptor in non-small cell lung cancer. Mod Pathol 8:450-455.
45. Sozzi G, Miozzo M, Tagliabue E, Calderone C, Lombardi L, Pilotti S, Pastorino U, Pierotti MA, DellaPorta G. 1991. Cytogenetic abnormalities and overexpression of receptors for growth factors in normal bronchial epithelium and tumor samples of lung cancer patients. Cancer Res 51:400-404.
46. Sugimura H, Weston A, Caporaso N, Shields PG, Bowman ED, Metcalf RA, Harris CC. 1991. Biochemical and molecular epidemiology of cancer. Biomed Environ Sci 4:73:92.
47. Suwa H, Ohshio G, Okada N, Wang Z, Fukumoto M, Imamura T, Imamura M. 1997. Clinical significance of serum p53 antigen in patients with pancreatic carcinomas. Gut 40:647-653.
48. Taylor JA, Watson MA, Devereux TR, Michels RY, Saccomanno G, Anderson M. 1994. p53 mutations hotspot in radon-associated lung cancer. Lancet 343:86-87.
49. Trivers GE, Cawley HL, DeBenedetti VM, Hollstein M, Marion MJ, Bennett WP, Hoover ML, Price CC, Tamburro CC, Harris CC. 1995. April-p53 antibodies in sera of workers occupationally exposed to vinyl chloride. J Nat Cancer Inst 87:1400-1407.
50. Trumper L, Jung W, Dahl G, Diehl V, Gause A, Pfrundschuh M. 1994. Interleukin-7, interleukin-8, soluble TNF receptor and p53 protein levels are elevated in the serum of patients with Hodgkin's disease. Ann Oncol 5:93-96.
51. Vähäkangas KH, Samet JM, Metcalf RA, Welsh JA, Bennett WP, Lane DP, Harris CC. 1992. Mutations of p53 and ras genes in radon-associated lung cancer from uranium miners. Lancet 339: 576-580.
52. Vahrenholz C, Popp W, Wüst T, Rietschel F, Bauer P, Konietzko N, Norpoth K. 1997. DNA damage in blood lymphocytes of former uranium miners. Eur J Cancer 33(Suppl 8):S14.
53. Wang X, Christiani DC, Wiencke JK, Fischbein M, Xu X, Cheng J, Merk E, Wain J, Kelsey KT. 1995. Mutations in the p53 gene in lung cancer are associated with cigarette smoking and asbestos exposure. Cancer Epidemiol Biomarkers Prev 4:543-548.
54. Weissfeld JL, Larsen RD, Niman HL, Kuller LH. 1994. Evaluation of oncogene-related proteins in serum. Cancer Epidemiol Biomarkers Prev 3:57-62.
55. Wild CP, Ridanpää M, Antilla S, Lubin R, Soussi T, Husgavfel-Pursianen K, Vainio H. 1995. p53 antibodies in the sera of lung cancer patients: comparison with p53 mutations in the tumor tissue. Int J Cancer 64:176-181.
56. Winter SF, Sekido Y, Minna JD, McIntire D, Johnson BE, Gazdar AF, Carbone DP. 1993. Antibodies against autologous tumor cell proteins in patients with small-cell lung cancer: Associated with improved survival. J Nat Cancer Inst 85:2012-2018.
57. Wynford-Thomas D. 1991. Oncogenes and anti-oncogenes: The molecular basis of tumour behaviour. J Pathol 165:187-201.